References
- Gross D. M., Sweet C. S., Ulm E. H., Backlung E. P., Morris A. A., Weitz D., Bohn D. L., Wenger H. C., Vassil T. C., Stone C. A. Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-ala-L-pro and its ethyl ester (MK-421) on the angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo. J Pharm Exp Therap 1981; 216: 552–557
- Ferguson R. K., Vlasses P. H., Swanson B. N., Mojaverian P., Hichens M., Irvin J., Huber P. B. Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clin Pharmacol Therap 1982; 32: 48–53
- Sweet C. S., Gross D. M., Arbegast P. T., Gaul S. L., Britt P. M., Ludden C. T., Weitz D., Stone C. A. Antihypertensive activity of N-[(S)-1- (ethoxycarbonyl) - 3 - phenyl - propyl] - L - ala - L - pro (MK-421) an orally active converting enzyme inhibitor. J Pharm Exp Therap 1981; 216: 558–566
- Gavras H., Waeber B., Gavras I., Biollez J., Brunner H. R., Davies R. O. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor “MK-421”. Lancet 1981; 2: 543–547
- Hashimoto K., Taira N., Chiba S., Endoh M., Kokubun M., Kokubun H., Iijima T., Kimura T., Kubota K., Oguro K. Cardiohemodynamic effects of BAY-a-1040 in the dog. Arzneim-Forsch 1972; 22: 15–21
- Murakami M., Murakami E., Takekoshi N., Txuchiya M., Kin T., Onol T., Takeuchi N., Funatsu T., Hara S., Ishise S., Mifune J., Maeda M. Antihypertensive effect of 4 (-2′Nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3–5-dicarbonic acid and dimethylester (Nifedipine, Bay-a-1040), a new coronary dilator. Jap Heart J 1972; 13: 128–135
- Lederballe-Pedersen O., Mikkelsen E. Acute and chronic effects of nifedipine in arterial hypertension. Europ J Clin Pharmacol 1978; 14: 375–381
- Lasser V. U., Meurer K. A., Kaufmann W. Zur Klinischen Bawertung der kombinationsbehandlung von nifedipin mit verschiedenen antihypertensiva. Arzneim-Forsch/Drug Research 1977; 27: 676–681
- Lederballe-Pedersen O., Christensen C. K., Middelson E., Ramsch K. D. Relationship between the antihypertensive effect and steady state plasma cncentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent. Eur J Clin Pharmacol 1980; 18: 287–293
- Ito T., Woo J., Haning R., Horton R. A radioimmunoassay for aldosterone in human peripheral plasma including a comparison of alternate techniques. J Clin Endocrinol 1972; 34: 106–112
- Swanson B. N., Hichens M., Mojaverian P., Ferguson R. K., Vlasses P. H., Dudash M. Angiotensin converting enzyme activity in serum: relationship to enzyme inhibitor in vivo, in vitro. Res Comm Chem Pathol Pharmacol 1981; 33: 525–536
- Kubo T., Fujie K., Yamashita M., Misu Y. Antihypertensive effects of nifedipine on conscious normotensive and hypertensive rats. J Pharm Dyn 1981; 4: 294–300
- Soto M. E., Thibonnier M., Site O., Menard J., Corvol P., Milliez P. Antihypertensive and hormonal effects of single oral doses of captopril and nifedipine in essential hypertension. Eur J Clin Pharm 1981; 20: 157–161
- Fagard R., Lijnen P., Amery A. Hemodynamic response to acute and chronic angiotensin converting enzyme inhibition (captopril) in hypertensive patients. Angiotensin Converting Enzyme Inhibitors, Mechanisms of Action and Clinical Implications., Horovitz. Urban and Schwarzenberg. 1981
- Wei J. W., Janis R. A., Daniel E. E. Calcium accumulation and enzymatic activities of subcellular fractions from aortas and ventricles of geneticallyhypertensive rats. Circ Res 1976; 39: 133–137
- Stornello M., DiRao G., Iachello M., Pisani R., Scapellato L., Pedrinelli R., Salvelli A. Hemodynamic and humoral interactions between captopril and nifedipine. Hypertension 1983; 5: III154–III156
- Fray JCS. Stimulus secretion coupling of renin. Circ Res 1980; 47: 485–492
- Hashimoto K., Ono H., O'Hara N. Blockade of renal auto-regulatory vasoconstriction by calcium antagonists. Springer, Berlin Heidelberg, New York 1978; 221–229